Paper Details

  1. Home
  2. Paper Details

The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells.

Author: QiWenxiu, SongBailin, SunLiping, SunLiwei, XuXiaohao, YanXiuci, ZhaoDaqing

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. Cytarabine is a drug that is commonly used to treat AML. However, many patients develop resistance to cytarabine. This study investigated the effects of compound K, a metabolite of ginsenoside, in combination with cytarabine on AML cells. The study found that compound K and cytarabine synergistically inhibited the growth of AML cells and induced apoptosis. The study concluded that compound K may be a promising agent for overcoming resistance to cytarabine in AML.
Paper Details　
Original Abstract of the Article :
AML is a kind of hematological malignant tumor that urgently requires different treatment options in order to increase the cure rate and survival rate. Cytarabine (ara-C) is currently the main drug used to treat AML patients and is usually combined with different chemotherapeutic agents. However, du...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.biopha.2020.110812

データ提供：米国国立医学図書館（NLM）

Synergistic Therapy for Acute Myeloid Leukemia: A New Dawn

Cancer research is a dynamic field, with scientists constantly searching for new and effective therapies to combat this devastating disease. This study explores the potential of a synergistic combination of cytarabine (ara-C) and ginsenoside compound K to treat acute myeloid leukemia (AML). The study investigates the mechanism of action of this combination, focusing on its ability to induce DNA damage in AML cells. The authors demonstrate the synergistic effect of this combination, suggesting its potential as a novel treatment strategy for AML.

Combating AML: Harnessing the Power of Synergistic Therapy

The study's findings highlight the potential of a synergistic combination of ara-C and ginsenoside compound K in treating AML. This combination holds promise for overcoming ara-C resistance, a major challenge in AML treatment. The study underscores the importance of exploring novel combination therapies in the fight against cancer, leveraging the unique properties of different drugs to achieve greater therapeutic efficacy.

A New Oasis in the Desert of Cancer Treatment: Synergistic Therapy for AML

This research offers a glimmer of hope for AML patients, suggesting that a combination of ara-C and ginsenoside compound K could be a promising new treatment option. The study's findings pave the way for further clinical evaluation of this synergistic combination, potentially leading to improved treatment outcomes and a greater chance of survival for AML patients.

Dr.Camel's Conclusion

This research offers a promising new approach to treating acute myeloid leukemia, demonstrating the potential of a synergistic combination of cytarabine and ginsenoside compound K to overcome drug resistance and improve treatment outcomes. The study emphasizes the importance of exploring novel combination therapies in the fight against cancer, leveraging the unique properties of different drugs to achieve greater therapeutic efficacy. This research serves as a reminder of the ongoing advancements in cancer research and the potential of new therapies to transform patient care.

Date :
  1. Date Completed 2021-02-19
  2. Date Revised 2021-02-19
Further Info :

Pubmed ID

33059263

DOI: Digital Object Identifier

10.1016/j.biopha.2020.110812

Related Literature

Article Analysis
・Effects of cytarabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.